Sanofi Aventis Pakistan Ltd. announced Financial Results for the period ended June 30, 2017.
The company’s Net Sales for the period increased by 16 percent in the outgoing year, whereas the Profit after Taxation for the Period increased by 152 percent.
The board has did not recommend any Cash Dividend, bonus or right shares.
Comparison of Key Financials
|
Unconsolidated Profit and Loss Account – For the Six Months Ended |
||||
|
Key Financials |
Jan – June, 2017 |
Jan – Jun, 2016 |
% Change |
Common Size 2017 |
|
Amounts in PKR ‘000 |
|
|||
|
Net Sales |
6,629,117 |
5,715,606 |
15.98% |
100% |
|
Cost of SalesGross Profit |
4,156,510 |
3,779,998 |
9.96% |
91% |
|
Gross Profit |
2,472,607 |
1,935,608 |
27.74% |
47% |
|
Dist: & Marketing Expenses |
1,122,146 |
1,165,334 |
-3.71% |
28% |
|
Admin: Expenses |
198,623 |
148,609 |
33.65% |
4% |
|
Other Expenses |
210,656 |
76,393 |
175.75% |
2% |
|
Other income |
27,616 |
17,342 |
59.24% |
0% |
|
Operating Profit |
968,798 |
562,614 |
72.20% |
14% |
|
Finance Costs |
27,388 |
93,583 |
-70.73% |
2% |
|
Profits before Taxation |
941,410 |
469,031 |
100.71% |
11% |
|
Taxation |
328,799 |
226,476 |
45.18% |
5% |
|
Net Profit/(Loss) |
612,611 |
242,555 |
152.57% |
6% |
|
EPS – Basic & Diluted |
63.52 |
25.15 |
152.56% |
0% |
Company release on Earnings Report can be accessed here.
